Education
About Us
Working with TipRanks
Follow Us
Everest Medicines Ltd. (HK:1952)
:1952
Total Valuation
Everest Medicines Ltd. has a market cap or net worth of HK$22.30B. The enterprise value is HK$19.31B.
Market CapHK$22.30B
Enterprise ValueHK$19.31B
Share Statistics
Everest Medicines Ltd. has 350,920,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding350,920,040
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Everest Medicines Ltd.’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -24.00%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-24.00%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee1.06M
Profits Per Employee-1.57M
Employee Count665
Asset Turnover0.14
Inventory Turnover12.63
Valuation Ratios
The current PE Ratio of Everest Medicines Ltd. is ―. Everest Medicines Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value3.58
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio―
Income Statement
In the last 12 months, Everest Medicines Ltd. had revenue of 706.68M and earned -1.04B in profits. Earnings per share was -3.24.
Revenue706.68M
Gross Profit528.89M
Operating Income-1.12B
Pretax Income-1.04B
Net Income-1.04B
EBITDA-670.04M
Earnings Per Share (EPS)-3.24
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Everest Medicines Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change190.85%
50-Day Moving Average67.59
200-Day Moving Average51.52
Relative Strength Index (RSI)40.49
Average Volume (3m)7.87M
Important Dates
Everest Medicines Ltd. upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Everest Medicines Ltd. as a current ratio of 2.54, with Debt / Equity ratio of 14.13%
Current Ratio2.54
Quick Ratio2.52
Debt to Market Cap0.04
Net Debt to EBITDA0.46
Interest Coverage Ratio-50.34
Taxes
In the past 12 months, Everest Medicines Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Everest Medicines Ltd. EV to EBITDA ratio is -21.31, with an EV/FCF ratio of -19.17.
EV to Sales20.21
EV to EBITDA-21.31
EV to Free Cash Flow-19.17
EV to Operating Cash Flow-21.01
Balance Sheet
Everest Medicines Ltd. has HK$1.60B in cash and marketable securities with HK$575.61M in debt, giving a net cash position of -HK$1.03B billion.
Cash & Marketable SecuritiesHK$1.60B
Total DebtHK$575.61M
Net Cash-HK$1.03B
Net Cash Per Share-HK$2.93
Tangible Book Value Per ShareHK$5.67
Margins
Gross margin is 74.84%, with operating margin of -158.07%, and net profit margin of -147.36%.
Gross Margin74.84%
Operating Margin-158.07%
Pretax Margin-147.36%
Net Profit Margin-147.36%
EBITDA Margin-94.82%
EBIT Margin-110.41%
Analyst Forecast
The average price target for Everest Medicines Ltd. is HK$64.27, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$64.27
Price Target Upside1.13% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast102.73%
EPS Growth Forecast38.42%